CMV70-3P miRNA contributes to the CMV mediated glioma stemness and represents a target for glioma experimental therapy
Metrics: PDF 926 views | HTML 1932 views | ?
Ilya V. Ulasov1,2,3, Natalya V. Kaverina3,4, Dhimankrishna Ghosh1, Marya A. Baryshnikova2,3, Zaira G. Kadagidze3, Apollon I. Karseladze3, Anatoly Y. Baryshnikov2,3, Charles S. Cobbs1
1Swedish Neuroscience Institute, Center for Advanced Brain Tumor Treatment, Seattle, WA, 98122, USA
2Institute of Experimental Diagnostics and Therapy of Tumors, N.N. Blokhin Russian Cancer Research Center, Moscow, 115478, Russia
3NN. Blokhin Cancer Research Center, RAMN, Moscow, 115478, Russia
4Current employment: Division of Nephrology, University of Washington, Seattle, 98109, WA, USA
Ilya V. Ulasov, email: Ilya.Ulasov@Swedish.org
Charles S. Cobbs, email: Charles.Cobbs@Swedish.org
Keywords: brain tumor, cytomegalovirus, glioma stem cells, miRNA
Received: November 17, 2015 Accepted: July 26, 2016 Published: August 10, 2016
Glioblastoma multiforme (GBM) is a rapidly progressive brain tumor with a median survival of 15–19 months. Therapeutic resistance and recurrence of the disease is attributed to cancer stem cells (CSC). Here, we report that CMV70-3P miRNA encoded by CMV increases GBM CSC stemness. Inhibition of CMV70-3P expression using oligo inhibitors significantly attenuated the ability of primary glioma cells to proliferate and form neurospheres. At the molecular level, we show that CM70-3P increases expression of cellular SOX2. Collectively, these findings indicate that CMV70-3P is a potential regulator of CMV- mediated glioma progression and cancer stemness.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.